NYSE:EW
Edwards Lifesciences Corp
Edwards Lifesciences Corp's revenue grew 11.5% in fiscal 2025 to $6.1B while operating margin fell to 20.8%. Free cash flow was $1.3B, 22.0% of revenue, and the diluted share count fell 2.3%.Summary generated from Edwards Lifesciences Corp's SEC filings. Latest annual report filed Feb 25, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$6.1B
Revenue growth+11.5%
Revenue, 5-yr CAGR+6.7%
Gross margin78.0%
Operating margin20.8%
Net margin17.7%
ROIC13.5%
Return on equity10.6%
Debt / equity0.06
Free cash flow$1.3B
FCF margin22.0%
Share count change−2.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 5,233 | 4,464 | 5,010 | 5,440 | 6,068 |
| Operating income | 1,690 | 1,498 | 1,309 | 1,379 | 1,264 |
| Net income | 1,503 | 1,522 | 1,402 | 4,175 | 1,074 |
| Free cash flow | 1,406 | 974 | 643 | 290 | 1,335 |
Recent filings
- 4Insider transaction report
Oct 8, 2026 - 4Insider transaction report
Sep 14, 2026 - 8-KDirector or officer change
Aug 28, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Jul 23, 2026 - 8-KDirector or officer change
May 8, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026 - 8-KDirector or officer change
May 4, 2026